Advertisement
U.S. Markets open in 6 hrs 54 mins

MBX Biosciences, Inc. (MBX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W
23.89-0.18 (-0.75%)
At close: 04:00PM EDT
23.89 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close24.07
Open23.15
Bid23.77 x 100
Ask24.50 x 100
Day's Range23.10 - 24.82
52 Week Range20.28 - 26.19
Volume107,047
Avg. Volume205,118
Market Cap797.537M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.48
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.25
  • TipRanks

    Opening Day: Another trio of biotech IPOs make Friday debut

    The Partners Group-backed KinderCare sold 24 million shares for $24 each this Tuesday. At the IPO price, the childhood education company had a market value of $2.74B, based on the outstanding shares. Sky Quarry, Click Holdings, and SKK Holdings also opened for trading this week. Meanwhile, a new trio of biotech companies’ shares came to market on Friday as Upstream Bio, Ceribell and Camp4 Therapeutics each made their public debut. In mid-September, Bicara Therapeutics (BCAX), MBX Biosciences (MB

  • GlobeNewswire

    MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

    CARMEL, Ind., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that both the rationale and design of the Phase 2 Avail™ trial of MBX 2109, the Company’s potential long-acting parathyroid hormone (PTH) peptide prodrug, in adults with hypoparathyroidism (HP) were featured in a poster p